Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

Año publicación: 2025

Subir documento: https://drive.google.com/file/d/1LbD7yXL3-Lp-nMkJYK58ApWOy9PV8UWm/view?usp=sharing

Nombre investigadores: Darren K. McGuire, Nikolaus Marx, Sharon L. Mulvagh, John E. Deanfield, Silvio E. Inzucchi, Rodica Pop-Busui, Johannes F.E. Mann, Scott S. Emerson, Neil R. Poulter, F.Med.Sci., Mads D.M. Engelmann, M.D., Ph.D., Maria Sejersten Ripa, M.D., M.D.Sc., G. Kees Hovingh, Kirstine Brown-Frandsen, Stephen C. Bain, Matthew A. Cavender, Mette Gislum, Jens-Peter David, John B. Buse, for the SOUL Study Group